{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:23:26Z","timestamp":1791829406370,"version":"4.3.4"},"reference-count":31,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1080\/03007995.2021.1891035","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T20:39:39Z","timestamp":1613680779000},"page":"867-877","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder"],"prefix":"10.1080","volume":"37","author":[{"given":"Kelesitse","family":"Phiri","sequence":"first","affiliation":[{"name":"Optum Epidemiology","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Linder","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Margulis","sequence":"additional","affiliation":[{"name":"Epidemiology, RTI Health Solutions","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Suehs","sequence":"additional","affiliation":[{"name":"Humana Healthcare Research","place":["Humana, Louisville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Arana","sequence":"additional","affiliation":[{"name":"Epidemiology, RTI Health Solutions","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Bahmanyar","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Optum Epidemiology","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Enger","sequence":"additional","affiliation":[{"name":"Optum Epidemiology","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libby","family":"Horter","sequence":"additional","affiliation":[{"name":"Humana Healthcare Research","place":["Humana, Louisville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Odsbu","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Olesen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Perez-Gutthann","sequence":"additional","affiliation":[{"name":"Epidemiology, RTI Health Solutions","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Sahlertz","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Appenteng","sequence":"additional","affiliation":[{"name":"Pharmacovigilance, Astellas Pharma US","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"de Vogel","sequence":"additional","affiliation":[{"name":"Pharmacovigilance, Astellas Pharma Europe B.V","place":["Leiden, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Seeger","sequence":"additional","affiliation":[{"name":"Optum Epidemiology","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20798"},{"key":"e_1_3_5_4_1","unstructured":"Rahnama\u2019i S. Overactive bladder. Current Definition. 2018. [cited 2021 Jan 14]. Available from: https:\/\/www.ics.org\/committees\/standardisation\/terminologydiscussions\/overactivebladder."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22609"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S93636"},{"key":"e_1_3_5_7_1","first-page":"CD013108","article-title":"Surgery for women with pelvic organ prolapse with or without stress urinary incontinence","volume":"8","author":"Baessler K","year":"2018","unstructured":"Baessler K, Christmann-Schmid C, Maher C, et\u00a0al. Surgery for women with pelvic organ prolapse with or without stress urinary incontinence. Cochrane Database Syst Rev. 2018;8:CD013108.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.04.010"},{"key":"e_1_3_5_9_1","unstructured":"Astellas Pharma US I. MYRBETRIQ prescribing information. 2018. [cited 2021 Jan 14]. Available from: https:\/\/www.us.astellas.com\/docs\/Myrbetriq_WPI.pdf."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.048"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.017"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-013-2042-x"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12053"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12649"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.02.077"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3891"},{"key":"e_1_3_5_18_1","unstructured":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 5). 2020. [cited 2021 Jan 14]. Available from: http:\/\/www.encepp.eu\/standards_and_guidances."},{"key":"e_1_3_5_19_1","unstructured":"Centers for Disease Control and Prevention. International Classification of Diseases Ninth Revision (ICD-9). 2020. [cited 2021 Jan 14]. Available from: https:\/\/www.cdc.gov\/nchs\/icd\/icd9.htm."},{"key":"e_1_3_5_20_1","unstructured":"Centers for Disease Control and Prevention. International Classification of Diseases Tenth Revision Clinical Modification (ICD-10-CM). [cited 2021 Jan 14]. Available from: https:\/\/www.cdc.gov\/nchs\/icd\/icd10cm.htm."},{"key":"e_1_3_5_21_1","unstructured":"Centers for Disease Control and Prevention. International Classification of Diseases Ninth Revision Clinical Modification (ICD-9-CM). 2020. [cited 2021 Jan 14]. Available from: https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm."},{"key":"e_1_3_5_22_1","unstructured":"World Health Organization. International Classification of Diseases for Oncology 3rd Edition (ICD-O-3). 2020. [cited 2021 Jan 14]. Available from: https:\/\/www.who.int\/classifications\/icd\/adaptations\/oncology\/en\/."},{"key":"e_1_3_5_23_1","unstructured":"Surveillance Epidemiology and End Results. SEER Cancer Statistics Review 1975\u20132009 (vintage 2009 populations). Table 1.4. Age-adjusted SEER incidence and US death rates and 5-year relative survival (percent) by primary cancer site sex and time period. [cited 2021 Jan 14]. Available from: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2009_pops09\/browse_csr.php."},{"key":"e_1_3_5_24_1","unstructured":"Eurostat. Statistics Explained. Cancer statistics \u2013 specific cancers. 2019. [cited 2021 Jan 14]. Available from: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/pdfscache\/39738.pdf."},{"key":"e_1_3_5_25_1","unstructured":"Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques (paper 214\u201326). Paper presented at: SUGI 26 Proceedings (Proceedings of the 26th annual SAS users group international conference) Long Beach CA April 22\u201325 2001. 2001. [cited 2021 Jan 14]. Available from: https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/sugi26\/p214-26.pdf"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_3_5_27_1","volume-title":"Modern epidemiology","author":"Rothman KJ.","year":"2008","unstructured":"Rothman KJ. Modern epidemiology. 3rd ed. Philadelphia (PA): Wolters Kluwer Health; 2008.","edition":"3"},{"key":"e_1_3_5_28_1","unstructured":"Comprehensive Meta-Analysis (CMA) Software. [cited 2021 Jan 14]. Available from: https:\/\/www.meta-analysis.com\/."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S186842"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12965"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1932"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2454"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2021.1891035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:09:15Z","timestamp":1770890955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2021.1891035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,4]]}},"alternative-id":["10.1080\/03007995.2021.1891035"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2021.1891035","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}